Review Compares Efficacy, Safety of Treatments for Hidradenitis Suppurativa

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on July 7, 2025.

via HealthDay

MONDAY, July 7, 2025 -- The efficacy and safety of currently approved and pipeline medications for moderate-to-severe hidradenitis suppurativa (HS) are compared in a systematic literature review and network meta-analysis published online July 2 in JAMA Dermatology.

Amit Garg, M.D., from Northwell in New Hyde Park, New York, and colleagues compared the efficacy, safety, and tolerability of treatments for moderate-to-severe HS in a systematic literature review of phase 2 and 3 randomized clinical trials. Twenty-five trials, including 5,767 patients and 39 unique treatments, had available Hidradenitis Suppurativa Clinical Response (HiSCR)-50 data.

The researchers found that sonelokimab (120 mg every four weeks and 240 mg every two weeks), lutikizumab (300 mg every two weeks), adalimumab (40 mg once per week), bimekizumab (320 mg every two weeks and 320 mg every four weeks), povorcitinib (15 mg once a day), and secukinumab (300 mg every four weeks and 300 mg every two weeks) were associated with significantly higher HiSCR-50 response rates compared with placebo. The differences between adalimumab (40 mg once per week) and other targeted treatments were mostly not statistically significant. The percentage of patients experiencing serious adverse events ranged from 0 to 10, 0 to 8, and 0 to 6 percent in the placebo groups, the adalimumab (40 mg once per week) groups, and the other active treatment groups, respectively.

"These data do not provide strong support for the superiority of one treatment over adalimumab, or vice versa," the authors write.

One author disclosed ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-07-08 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords